X

Vous n'êtes pas connecté

Headings :

Maroc Maroc - DRUGS.COM - Pharma Industry News - 09/07/2024 15:54

Intensity-Modulated Radiotherapy Recommended for Locally Advanced Lung Cancer

TUESDAY, July 9, 2024 -- Intensity-modulated radiotherapy (IMRT) is recommended for locally advanced non-small cell lung cancer (NSCLC) and appears to have good long-term outcomes, according to a study published online June 27 in JAMA...

Articles similaires

Sorry! Image not available at this time

WCLC 2025: Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

oncologynews.com.au - 09/Sep 15:53

A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate...

Sorry! Image not available at this time

WCLC 2025: Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds

oncologynews.com.au - 09/Sep 15:53

A combination of iza-bren (BL-B01D1), a novel bispecific antibody-drug conjugate (ADC), with osimertinib demonstrated a 100% objective response rate...

Sorry! Image not available at this time

Novocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)

healthtechzone.com - 15/Sep 11:00

Sorry! Image not available at this time

WCLC 2025: New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

oncologynews.com.au - 09/Sep 16:30

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with...

Sorry! Image not available at this time

WCLC 2025: New antibody-drug conjugate shows promising efficacy in EGFR-mutated NSCLC patients

oncologynews.com.au - 09/Sep 16:30

A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with...

Sorry! Image not available at this time

HypoRT with concurrent chemotherapy reduces treatment time and toxicity for patients with LS-SCLC

news.medical.net - 08/Sep 17:10

A multi-center, randomized phase III trial has found that a three-week hypofractionated radiotherapy (HypoRT) schedule with concurrent chemotherapy...

Sorry! Image not available at this time

WCLC 2025: Study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

oncologynews.com.au - 13/Sep 16:31

A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced...

Sorry! Image not available at this time

WCLC 2025: Study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC

oncologynews.com.au - 13/Sep 16:31

A new analysis from the COMPEL trial shows that patients with EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) who experienced...

Sorry! Image not available at this time

Immunotherapy: 10 years of hope for lung cancer patients in Việt Nam

wn.com - 15/Sep 12:28

For nearly 10 years, immunotherapy, since it was first introduced into Vietnam by MSD and approved by Vietnam’s Ministry of Health, has opened a new...

Sorry! Image not available at this time

WCLC 2025: Nivolumab maintains quality of life and reduces symptom deterioration in resectable NSCLC

oncologynews.com.au - 13/Sep 16:19

An analysis from the Phase 3 CheckMate 77T trial confirms that perioperative nivolumab does not compromise health-related quality of life (HRQoL) in...

Latest releases